Johnson & Johnson vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?
The article compares Johnson & Johnson and Vertex Pharmaceuticals as investment options for 2027. JNJ is a diversified healthcare giant with $99.3B in revenue and strong cash flow, while VRTX is a specialized biotech leader with $13B in revenue focused on cystic fibrosis and expanding into gene therapies. Despite VRTX's higher growth rate and lower P/E ratio, JNJ is recommended as the better buy due to its superior valuation multiples (P/E 25.4x vs 29.6x, P/S 6.8x vs 10.5x) and established market position.



